$2.35 Billion is the total value of Tekla Capital Management LLC's 143 reported holdings in Q4 2016. The portfolio turnover from Q3 2016 to Q4 2016 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| XBI | New | SPDR S&P Biotech ETFetf | $10,595,000 | – | 179,000 | +100.0% | 0.45% | – |
| CCP | New | Care Capital Properties, Inc. | $8,626,000 | – | 345,022 | +100.0% | 0.37% | – |
| MYOV | New | Myovant Sciences Ltd. | $4,976,000 | – | 400,000 | +100.0% | 0.21% | – |
| CHRS | New | Coherus Biosciences, Inc. | $2,534,000 | – | 90,000 | +100.0% | 0.11% | – |
| ADMS | New | Adamas Pharmaceuticals, Inc. | $2,121,000 | – | 125,504 | +100.0% | 0.09% | – |
| NBRV | New | Nabriva Therapeutics AGsponsored adr | $2,083,000 | – | 350,000 | +100.0% | 0.09% | – |
| HR | New | Healthcare Realty Trust, Inc. | $2,062,000 | – | 68,000 | +100.0% | 0.09% | – |
| ACHN | New | Achillion Pharmaceuticals, Inc. | $1,833,000 | – | 443,851 | +100.0% | 0.08% | – |
| WELL | New | Welltower Inc. | $1,432,000 | – | 21,400 | +100.0% | 0.06% | – |
| XLRN | New | Acceleron Pharma, Inc. | $1,390,000 | – | 54,450 | +100.0% | 0.06% | – |
| HCP | New | HCP, Inc. | $1,352,000 | – | 45,500 | +100.0% | 0.06% | – |
| HTA | New | Healthcare Trust of America, Inc.class a | $1,339,000 | – | 46,000 | +100.0% | 0.06% | – |
| ONCE | New | Spark Therapeutics, Inc. | $1,213,000 | – | 24,300 | +100.0% | 0.05% | – |
| GMRE | New | Global Medical REIT Inc. | $655,000 | – | 73,400 | +100.0% | 0.03% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-02-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Gilead Sciences, Inc. | 41 | Q2 2023 | 12.4% |
| Amgen, Inc. | 41 | Q2 2023 | 5.8% |
| Biogen Inc. | 41 | Q2 2023 | 6.5% |
| Vertex Pharmaceuticals Incorporated | 41 | Q2 2023 | 5.3% |
| Regeneron Pharmaceuticals, Inc. | 41 | Q2 2023 | 9.1% |
| Illumina, Inc. | 41 | Q2 2023 | 3.4% |
| BioMarin Pharmaceutical Inc. | 41 | Q2 2023 | 2.9% |
| Teva Pharmaceutical Industries Ltd. | 41 | Q2 2023 | 3.2% |
| Neurocrine Biosciences, Inc. | 41 | Q2 2023 | 1.4% |
| McKesson Corporation | 41 | Q2 2023 | 2.2% |
View Tekla Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Rallybio Corp | January 23, 2023 | 1,727,067 | 4.6% |
| Zyla Life SciencesSold out | January 29, 2021 | 0 | 0.0% |
| ARCA biopharma, Inc. | January 24, 2020 | 36,068 | 2.3% |
| Verona Pharma plc | February 12, 2019 | 5,296,845 | 4.9% |
| Alliqua BioMedical, Inc. | February 12, 2018 | 165,000 | 3.3% |
| PIERIS PHARMACEUTICALS, INC. | February 12, 2018 | 1,962,380 | 4.4% |
| Intellipharmaceutics International Inc. | February 13, 2015 | 2,184,000 | 9.0% |
| HERON THERAPEUTICS, INC. /DE/ | February 14, 2014 | 20,598,613 | 4.2% |
| MEDWAVE INC | February 14, 2012 | 1,277,372 | 9.8% |
| MZT Holdings, Inc. | February 14, 2012 | 2,553,420 | 4.0% |
View Tekla Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-08-10 |
| 13F-HR | 2023-05-10 |
| 13F-HR | 2023-02-10 |
| SC 13G/A | 2023-01-23 |
| 13F-HR | 2022-11-01 |
| 13F-HR | 2022-07-29 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-14 |
| SC 13G | 2022-01-21 |
| 13F-HR | 2021-11-12 |
View Tekla Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.